Patient-Focused Drug Development At 10: Where Does It Go From Here?
FDA may conduct more than the 20 required meetings by the end of fiscal year 2017, but how will the patient-focused drug development program find its place in helping generate new drugs?
You may also be interested in...
Will a meeting with the agency's new principal deputy commissioner help assure creation of new access point for patient engagement?
Patient Engagement Collaborative expected to invite stakeholders to discuss how patient interaction with FDA can improve.
FDA floats idea of central office to coordinate patient engagement for symbolic as well as practical reasons.